Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling pathway inhibition in head and neck squamous cell carcinoma (HNSCC) both in vitr...

Full description

Bibliographic Details
Main Authors: Seong-Ho Kang, Bhumsuk Keam, Yong-Oon Ahn, Ha-Ram Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:OncoImmunology
Subjects:
head and neck squamous cell carcinoma
mek inhibitor
anti-pd-1/pd-l1 mab
immune recognition
immune infiltration
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1515057

Internet

http://dx.doi.org/10.1080/2162402X.2018.1515057

Similar Items